Blais, JE;
Wei, Y;
Knapp, M;
Wong, Ian;
Wei, L;
Chan, EW;
(2022)
Trends in PCSK9 Inhibitor Utilization in the United States, Europe and Other Countries: An Analysis of International Sales Data.
American Heart Journal
, 248
pp. 13-20.
10.1016/j.ahj.2022.02.008.
Preview |
Text
Wong_Trends in PCSK9 Inhibitor Utilization in the United States, Europe and Other Countries- An Analysis of International Sales Data_AAM.pdf Download (1MB) | Preview |
Abstract
First approved in July 2015, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are costly lipid-lowering drugs. Their utilization has important policy and clinical implications but has not been assessed across different geographical regions. The objective of this study was to describe trends in PCSK9 inhibitor adoption and utilization between 2015 and 2019 in the United States, Europe, and other countries.
Archive Staff Only
View Item |